These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

732 related items for PubMed ID: 18421415

  • 1. A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen.
    Wei SH, Yin W, An QX, Lei YF, Hu XB, Yang J, Lu X, Zhang H, Xu ZK.
    Arch Virol; 2008; 153(6):1021-9. PubMed ID: 18421415
    [Abstract] [Full Text] [Related]

  • 2. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.
    Zeng R, Li G, Ling S, Zhang H, Yao Z, Xiu B, He F, Huang R, Wei L.
    Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Immunizations with chimeric hepatitis B virus-like particles to induce potential anti-hepatitis C virus neutralizing antibodies.
    Vietheer PT, Boo I, Drummer HE, Netter HJ.
    Antivir Ther; 2007 Oct; 12(4):477-87. PubMed ID: 17668556
    [Abstract] [Full Text] [Related]

  • 5. Multigenotype HCV-NS3 recombinant vaccinia viruses as a model for evaluation of cross-genotype immunity induced by HCV vaccines in the mouse.
    Eisenbach C, Freyse A, Lupu CM, Weigand K, Ernst E, Hoyler B, Stremmel W, Bugert JJ, Encke J.
    Vaccine; 2006 Jun 12; 24(24):5140-8. PubMed ID: 16713033
    [Abstract] [Full Text] [Related]

  • 6. Oral immunization with attenuated Salmonella carrying a co-expression plasmid encoding the core and E2 proteins of hepatitis C virus capable of inducing cellular immune responses and neutralizing antibodies in mice.
    Cao J, Chen Z, Ren Y, Luo Y, Cao M, Lu W, Zhao P, Qi Z.
    Vaccine; 2011 May 09; 29(20):3714-23. PubMed ID: 21396407
    [Abstract] [Full Text] [Related]

  • 7. Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines.
    Siler CA, McGettigan JP, Dietzschold B, Herrine SK, Dubuisson J, Pomerantz RJ, Schnell MJ.
    Virology; 2002 Jan 05; 292(1):24-34. PubMed ID: 11878905
    [Abstract] [Full Text] [Related]

  • 8. Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen.
    Martin P, Parroche P, Chatel L, Barretto C, Beck A, Trépo C, Bain C, Lone YC, Inchauspé G, Fournillier A.
    J Med Virol; 2004 Nov 05; 74(3):397-405. PubMed ID: 15368525
    [Abstract] [Full Text] [Related]

  • 9. Enhanced and sustained CD8+ T cell responses with an adenoviral vector-based hepatitis C virus vaccine encoding NS3 linked to the MHC class II chaperone protein invariant chain.
    Mikkelsen M, Holst PJ, Bukh J, Thomsen AR, Christensen JP.
    J Immunol; 2011 Feb 15; 186(4):2355-64. PubMed ID: 21257961
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Immune responses of a recombined live Salmonella typhimurium SL3261 expressing a multi-epitope antigen of HCV].
    Huang J, Xie Y, Zhang Q, Shen X, Ren D.
    Wei Sheng Wu Xue Bao; 2000 Oct 15; 40(5):495-9. PubMed ID: 12548760
    [Abstract] [Full Text] [Related]

  • 14. Comparative immunogenicity analysis of modified vaccinia Ankara vectors expressing native or modified forms of hepatitis C virus E1 and E2 glycoproteins.
    Abraham JD, Himoudi N, Kien F, Berland JL, Codran A, Bartosch B, Baumert T, Paranhos-Baccala G, Schuster C, Inchauspé G, Kieny MP.
    Vaccine; 2004 Sep 28; 22(29-30):3917-28. PubMed ID: 15364440
    [Abstract] [Full Text] [Related]

  • 15. Development of a heterologous, multigenotype vaccine against hepatitis C virus infection.
    Encke J, Radunz W, Eisenbach C, Geib J, Gehrke S, Pfaff E, Stremmel W.
    Eur J Clin Invest; 2007 May 28; 37(5):396-406. PubMed ID: 17461986
    [Abstract] [Full Text] [Related]

  • 16. Murine antibodies against E2 and hypervariable region 1 cross-reactively capture hepatitis C virus.
    Esumi M, Ahmed M, Zhou YH, Takahashi H, Shikata T.
    Virology; 1998 Nov 10; 251(1):158-64. PubMed ID: 9813211
    [Abstract] [Full Text] [Related]

  • 17. An accelerated vaccine schedule with a poly-antigenic hepatitis C virus MVA-based candidate vaccine induces potent, long lasting and in vivo cross-reactive T cell responses.
    Fournillier A, Gerossier E, Evlashev A, Schmitt D, Simon B, Chatel L, Martin P, Silvestre N, Balloul JM, Barry R, Inchauspé G.
    Vaccine; 2007 Oct 16; 25(42):7339-53. PubMed ID: 17875349
    [Abstract] [Full Text] [Related]

  • 18. A liposomal peptide vaccine inducing CD8+ T cells in HLA-A2.1 transgenic mice, which recognise human cells encoding hepatitis C virus (HCV) proteins.
    Engler OB, Schwendener RA, Dai WJ, Wölk B, Pichler W, Moradpour D, Brunner T, Cerny A.
    Vaccine; 2004 Nov 15; 23(1):58-68. PubMed ID: 15519708
    [Abstract] [Full Text] [Related]

  • 19. Recombinant adenoviral vector expressing HCV NS4 induces protective immune responses in a mouse model of Vaccinia-HCV virus infection: a dose and route conundrum.
    Singh S, Vedi S, Li W, Samrat SK, Kumar R, Agrawal B.
    Vaccine; 2014 May 13; 32(23):2712-21. PubMed ID: 24631092
    [Abstract] [Full Text] [Related]

  • 20. Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model.
    El-Gogo S, Staib C, Lasarte JJ, Sutter G, Adler H.
    J Gene Med; 2008 Feb 13; 10(2):177-86. PubMed ID: 18076128
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.